Disclaimer: This article has been developed and funded by Daiichi Sankyo ... in breast and lung cancer, two of the most common cancers and biggest killers in our society. Precision medicines ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Antibody-drug conjugates (ADCs) took centre stage at the European Society ... in cancer research, care, and advocacy, kicked off following news of a $4 billion deal where Daiichi Sankyo sold ...

With certain government data currently being withheld, removed, or restored but partially redacted on the websites of ...

The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in ...

AstraZeneca and Daiichi Sankyo voluntarily withdraw regulatory filing for Dato-DXd in nonsquamous non-small cell lung cancer in the European Union. TOKYO & MUNICH, December 24, 2024--Daiichi ...

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...

Breast Cancer has impacted every group, but according to the American Cancer Society, Black women are more at risk.

Researchers have found that fewer sessions of higher dose vaginal cuff brachytherapy work just as well as more frequent, lower-dose treatments for endometrial cancer patients.

Historically, cancer care largely focused on the fight for survival. Now, thanks to advancements in screening and treatment, many patients are living decades beyond their diagnosis.

According to the American Cancer Society, one in two men and one in three women will be diagnosed with cancer at some point in their lifetimes. Whether you, a friend or loved one has been affected ...

Feb. 7, 2025 — Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to ... Personalized Cancer ...